The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I/II trial of ruxolitinib in combination with trastuzumab in metastatic HER2-positive breast cancer.
Kevin Kalinsky
No relevant relationships to disclose
Dow-Chung Chi
No relevant relationships to disclose
Shing Mirn Lee
No relevant relationships to disclose
Kerin B. Adelson
No relevant relationships to disclose
Katherine D. Crew
No relevant relationships to disclose
Ellen Chuang
No relevant relationships to disclose
Della Makower
No relevant relationships to disclose
Dawn L. Hershman
No relevant relationships to disclose
Andrea Califano
No relevant relationships to disclose
Jose Silva
No relevant relationships to disclose
Matthew A. Maurer
No relevant relationships to disclose